Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients.

Abstract

Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four patients. These effects are most likely related to loreclezole, as doses and plasma levels of the associated anti-epileptic drugs remained unchanged during the study. Loreclezole was tolerated well and no changes in haematological or biochemical parameters were observed.

• Authors: T Rentmeester, J Hulsman
• Journal: Epilepsy research (Epilepsy Res) Vol. 8 Issue 2 Pg. 166-9 (Mar 1991) ISSN: 0920-1211 [Print] Netherlands
• PMID: 2065645 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Triazoles
• loreclezole

Topics

• Adult
• Anticonvulsants (adverse effects, therapeutic use)
• Drug Resistance
• Drug Therapy, Combination
• Epilepsy (drug therapy, physiopathology)
• Female
• Humans
• Male
• Middle Aged
• Triazoles (adverse effects, therapeutic use)